ArticleCurrent drug therapy2008
Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.
Article in Current drug therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- PCR-based RFLP and ERIC-PCR patterns of Helicobacter pylori strains linked to multidrug resistance in Egypt.Scientific reports · 2024Observational
- Interplay between Amoxicillin Resistance and Osmotic Stress in Helicobacter pylori.Journal of bacteriology · 2022Article
- In vitro antibacterial activity of nimbolide against Helicobacter pylori.Journal of ethnopharmacology · 2022Article
- Toxin-Antitoxin Systems - A New Player in Morphological Transformation of Antibiotic-ExposedFrontiers in cellular and infection microbiology · 2021Article
- Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa.BMC gastroenterology · 2018Article
- Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis.Microbiology and molecular biology reviews : MMBR · 2018Review
- Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment forThe American journal of tropical medicine and hygiene · 2017Article
- Vaccine against Helicobacter pylori: Inevitable approach.World journal of gastroenterology · 2016Review
- Article
- Helicobacter pylori in Iran: A systematic review on the antibiotic resistance.Iranian journal of basic medical sciences · 2015Review
- Nontraditional therapies to treat Helicobacter pylori infection.Journal of microbiology (Seoul, Korea) · 2014Review
- The study of mutation in 23S rRNA resistance gene of Helicobacter pylori to clarithromycin in patients with gastrointestinal disorders in Isfahan - Iran.Advanced biomedical research · 2014Article
- The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.Antimicrobial agents and chemotherapy · 2012Article
- Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland.Gastroenterology research and practice · 2012Article
- Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran.Journal of microbiology (Seoul, Korea) · 2011Article
- Challenges of antibacterial discovery.Clinical microbiology reviews · 2011Review
- In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the world's population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.